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Smad anchor for receptor activation (SARA or ZFYVE9) has been proposed to mediate transforming
growth factor b (TGF-b) signaling by direct interaction with the non-activated Smad proteins and the
TGF-b receptors; however, these ﬁndings are controversial. We demonstrate no correlation between
SARA expression and the levels of TGF-b-induced phosphorylation of Smads in various B-cell lym-
phomas. Moreover, knockdown of SARA in HeLa cells did not interfere with TGF-b-induced Smad
activation, Smad nuclear translocation, or induction of TGF-b target genes. Various R-Smads and
TGF-b receptors did not co-immunoprecipitate with SARA. Collectively, our results demonstrate that
SARA is dispensable for functional TGF-b-mediated signaling.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The transforming growth factor b (TGF-b) proteins are members
of a large family of cytokines that regulate key biological functions,
including cell proliferation, differentiation and apoptosis [1,2]. Sig-
naling is induced by binding of TGF-b to the TGF-b type II receptor
(TbRII), which forms a heterotetrameric complex with the TGF-b
type I receptor (TbRI) and phosphorylates it. Activation of TbRI re-
lieves its inhibition and activates its catalytic kinase domain. This
again allows TbRI to activate the receptor-regulated Smad proteins
(R-Smads), Smad2/3 [3–5] and Smad1/5 [6,7], by phosphorylation
on serine residues. The activated Smad proteins form heteromeric
complexes with the common mediator Smad4 protein [8]. These
complexes translocate to the nucleus where they regulate gene
expression.
The FYVE-ﬁnger domain-containing proteins are a group of pro-
teins implicated in receptor modulation and signaling at the endo-
somal level. The double zinc-ﬁnger motifs in FYVE domains are
essential structural elements that provide a potential link between
membrane trafﬁcking and signaling. The FYVE-domain proteins
bind to phosphatidylinositol 3-phosphate (PtdIns(3)P), which is
enriched on endosomal membranes [9]. There exist at least 33 dif-
ferent FYVE-ﬁnger domain-containing proteins in humans andchemical Societies. Published by E
nology, Institute for Cancer
n Radium Hospital, P.O. Box
old).SARA (Smad anchor for receptor activation, or ZFYVE9) represents
one of the more well-characterized proteins in this family.
Previously, it has been suggested that the FYVE-ﬁnger domain
in SARA is essential for recruitment of unphosphorylated Smad2/
3 to the appropriate subcellular membrane compartment and in
close proximity to the activated TbRI [10,11]. Furthermore, it has
been suggested that TGF-b-induced phosphorylation of Smad2
leads to dissociation from SARA, followed by nuclear translocation
of Smad2 in complex with Smad4. However, contradictory results
have been reported [12,13], and currently it is unclear whether
SARA is essential in TGF-b signaling. SARA expression in T cells
has been demonstrated to negatively correlate with TGF-b suscep-
tibility [14].
Here we demonstrate that SARA expression levels in B-cell
lymphoma cell lines are variable and do not correlate with
TGF-b-induced activation of Smad proteins. We also present exper-
imental evidence that SARA is dispensable for TGF-b signaling in
HeLa cells.
2. Materials and methods
2.1. Cell culture
Burkitt lymphoma cell lines Ramos and BL-41, diffuse large
B-cell lymphoma cell line SUDHL-4 and follicular lymphoma cell
lines K-422 and ROS-50 were cultured in RPMI (PAA Laboratories,
Pasching, Austria) supplemented with penicillin and streptomycin
(PAA Laboratories) and 10% fetal bovine serum (PAA Laboratories).
HeLa cells were maintained in Dulbecco’s modiﬁed Eagle’s mediumlsevier B.V. All rights reserved.
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serum (HyClone, Thermo Scientiﬁc, MA, USA), penicillin and
streptomycin.
2.2. siRNA treatment
ON-Target Plus siRNAs were from Dharmacon (Thermo Scien-
tiﬁc). Pre-designed oligonucleotides included scrambled siRNA
(D-001810-01), siRNAs speciﬁc for ZFYVE9 (SARA; J-011939-05
and J-011939-06) and ZFYVE16 (Endoﬁn; L-020254-01; SMART-
pool). Oligonucleotides were complexed with Lipofectamine RNAi-
Max transfection reagent (Invitrogen, Life Technologies, Paisley,
UK) in Opti-mem (Gibco, Life Technologies) without serum, peni-
cillin and streptomycin, and added to cells at 50% conﬂuency in
Opti-mem at a ﬁnal siRNA concentration of 50 nM. After 24 h, cells
were maintained in DMEM for up to 120 h post-transfection. In
experiments where TGF-b was added, cells were serum starved
in Opti-mem over night. SARA knockdown was conﬁrmed for every
experiment conducted (Supplementary Fig. S1A, B and data not
shown).
2.3. Reagents
Carrier-free huTGF-b1 (10 ng/ml for B-cell lymphoma and
1 ng/ml for HeLa cells, except for Fig. 1B, where both BL-41 and
HeLa cells were treated with 10 ng/ml TGF-b) was purchased from
R&D Systems (MN, USA). The following primary antibodies were
used: rabbit anti-phospho-Smad2, -phospho-Smad1/5, -phospho-
Smad3, -Smad2, -Smad1, -Smad5, -Smad3, -TbRI and TbRII (Cell
Signalling Technology, MA, USA), rabbit anti-SARA, goat anti-actin,
goat anti-SARA, mouse anti-SARA (Santa Cruz, CA, USA) and rabbit
anti-endoﬁn (Proteintech Group, IL, USA). Secondary HRP-coupled
goat anti-rabbit, rabbit anti-mouse and rabbit anti-goat IgG were
purchased from Dako (Glostrup, Denmark) or Trueblot anti-rabbit
and anti-mouse IgG HRP from eBiosciences (CA, USA). Alexa488-
coupled goat anti-rabbit IgG was obtained from Jackson Immuno-
research (PA, USA).
2.4. Confocal microscopy
HeLa cells were grown on cover slips and ﬁxed in 4% parafor-
maldehyde (Electron Microscopy Sciences, PA, USA) in PBS for
15 min at room temperature and permeabilized in methanol forFig. 1. TGF-b-induced Smad phosphorylation is independent of SARA expression.
B-cell lymphoma cell lines (A and B) and HeLa cells (B) were serum starved for 24 h
and incubated with or without TGF-b for 1 h, lysed, and subjected to Western
immunoblotting analysis with the indicated primary antibodies. Shown is one
representative experiment out of three. Actin was used as loading control.10 min at 20 C. Smad2 was detected using rabbit anti-Smad2
(Cell Signalling Technologies). Alexa488 goat anti-rabbit IgG was
used for detection. Hoechst (Merck, NJ, USA) was used to stain
DNA.
Finally, cells were mounted in anti-fading mounting medium
(Dako) containing Hoechst (1 lg/ml) and examined in a Zeiss
LSM 710 confocal laser-scanning microscope (Carl Zeiss AG,
Germany). A Zeiss Plan-Apochromat 63/1.40 Oil DIC M27 objec-
tive was used. Image processing was performed with basic
software ZEN 2009 (Carl Zeiss AG) and Photoshop CS2 (Adobe,
CA, USA).
2.5. Western immunoblotting analysis
Cells were lysed in Tris lysis buffer, pH 6.8 (62.7 mM Tris–HCl,
10% (v/v) glycerol, 2.3% (w/v) SDS, 5% b-Mercaptoethanol, 1x pro-
tease inhibitor mixture (Complete Mini, Roche, Switzerland) and
1x phosphatase inhibitor mixture (PhosSTOP, Roche)). Lysates
were incubated at 95 C for 10 min, cleared by centrifugation at
15,700g for 5 min and protein concentrations were determined
with the BioRad (CA, USA) protein assay. Samples (30–40 lg/lane)
were run on 10% or 12% SDS–polyacrylamide gels (Pierce, IL, USA)
or TGX gels (BioRad) and transferred to PVDF membranes
(Millipore, MA, USA). Membranes were blocked in 5% non-fat dry
milk or 5% BSA (Sigma–Aldrich, MO, USA) in TBST, according to
the protocols of the antibody manufacturers. PVDF membranes
were incubated over night at 4 C with antibody diluted in 5%
non-fat dry milk or 5% BSA in TBST. HRP-conjugated anti-mouse,
-goat and -rabbit IgG antibodies, incubated for 60 min at room
temperature, were used followed by detection using ECL or ECL
Plus (GE Healthcare, NJ, USA).
2.6. Co-immunoprecipitation
Cells were lysed in Tris lysis buffer (50 mM Tris, 150 mM NaCl,
1% NP-40, 1 mM EDTA, 1x protease inhibitor mixture (Complete
Mini; Roche) and 1x phosphatase inhibitor mixture (PhosSTOP;
Roche). After centrifugation at 10,000g for 10 min and pre-clear-
ing with protein G-Dynabeads (Invitrogen) for 10 min, rabbit
anti-SARA, already conjugated to protein G-Dynabeads (4 lg/ml
anti-SARA and 100 ll Dynabeads per sample), were added to the ly-
sates, and incubated for 1 h at 4 C. The beads were washed 4 times
with lysis buffer before they were incubated at 95 C for 5 min in
SDS-lysis buffer and prepared for SDS–PAGE and immunoblotting
with the appropriate primary antibody. Trueblot anti-rabbit and
anti-mouse IgG HRP antibodies (eBioscience) followed by ECL or
ECL Plus were used for detection.
2.7. Real time RT-PCR analysis
RNA was isolated using the Absolutely RNA Miniprep kit (Strat-
agene, CA, USA) following the manufacturer’s instructions. RNA
concentration was obtained using NanoDrop-1000 Spectropho-
tometer (Thermo Scientiﬁc), and quality was assessed by gel elec-
trophoresis using 1.5% agarose gel. RNA was stored at 80 C.
Using the TaqMan kit (Applied Biosystems, Life Technologies),
cDNA was obtained from 1 lg RNA for each sample and 400 ng
RNA for the negative controls without reverse transcriptase (-RT).
Conditions: 10 min at 25 C, 40 min at 42 C and 10 min at 95 C.
Real-time RT-PCR was conducted with TaqMan Universal PCR
master mix (Applied Biosystems) with ID1 (HS00704053), ID2
(Hs00747379_m1), ID3 (HS00171409) and SARA (ZFYVE9)
(Hs01024383_m1) (Applied Biosystems) as target genes and
PGK-1 (HS99999906_m1) (Applied Biosystems) as the control
gene. cDNA corresponding to 10 ng RNA was used per reaction.
The samples had a total volume of 25 ll, and were run on ABI
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10 min at 95 C and 40 cycles of 15 s at 95 C and 1 min at 60 C.
Relative expression levels were calculated using the threshold cy-
cle DDCt method as described by the manufacturer’s protocol.
3. Results
3.1. SARA expression does not correlate to TGF-b-induced
phosphorylation of Smad proteins in B-cell lymphoma
To understand themechanisms behind the resistance to TGF-b in
B-cell lymphoma [15], we studied additional components of the
TGF-b signaling pathway. The FYVE-ﬁnger domain-containing pro-
tein SARA has been suggested to have a role in canonical TGF-b sig-
naling. We studied the expression of SARA in several B-cell
lymphoma cell lines and found it to be expressed at variable levels
in the different cell lines. SARA was expressed in three of the cell
lines (BL-41, ROS-50 and K-422), with BL-41 showing the highest
expression (Fig. 1A). Notable, TGF-b induced the strongest phos-
phorylation of Smad2 in the SARA-negative cell line Ramos
(Fig. 1A). The expression of Smad2 was similar throughout the cell
lines, and did not change upon TGF-b stimulation. In addition,
strong phosphorylation of Smad1/5was observed in three out of ﬁve
cell lines, as previously reported [15] (Fig. 1A), and, except K-422,
the cell lines expressed either Smad1 or Smad5. Smad3 and phos-
phorylation of Smad3 was only weakly detectable. Overall, our re-
sults demonstrated no correlation between TGF-b-induced Smad
activation and SARA expression, raising the possibility that SARA
might not be essential for TGF-b signaling in B-cell lymphoma.
3.2. Loss of SARA does not inﬂuence TGF-b-induced phosphorylation of
Smad proteins
To study the function of SARA in TGF-b signaling in more detail,
we used HeLa cells as they are easy to genetically manipulate, in
contrast to B cells. HeLa cells also demonstrated phosphorylation
of Smad2 and Smad1/5 upon TGF-b treatment and expressed SARA
at higher levels than the B-cell lymphoma cell line BL-41 (Fig. 1B).
Two different siRNAs against SARA were tested individually, and
very strong downregulation at the protein level was observed after
24 h with both siRNAs (Fig. 2A and data not shown). Efﬁcient
knockdown of SARA was still detected ﬁve days after transfection
(data not shown). Remarkably, despite virtually complete knock-
down of SARA protein, no signiﬁcant difference in TGF-b-induced
pSmad2 or pSmad1/5 levels were found when comparing control
and SARA knockdown cells (Fig. 2A and Supplementary Fig. S2).
However, a dispensable role of SARA in TGF-b-induced phosphory-
lation of Smad2 and Smad1/5 could possibly be caused by redun-
dant function of another FYVE domain-containing protein.
Endoﬁn (also known as ZFYVE16) represents the most homolo-
gous FYVE domain-containing protein to SARA (49% homology),
and has been reported to function as a Smad anchor for receptor
activation in bone morphogenetic protein (BMP) signaling [16].
To test whether Endoﬁn could substitute for SARA when the level
of SARA was reduced, we knocked down Endoﬁn using siRNA.
However, downregulation of Endoﬁn alone or together with SARA
did not alter the canonical TGF-b signaling (Fig. 2A). These results
suggest that Endoﬁn has no compensatory role in substituting for
SARA in TGF-b-induced effects in SARA-knockdown cells.
3.3. SARA does not inﬂuence TGF-b target-gene induction
It is known that TGF-b-activated Smad proteins translocate
from the cytosol to the nucleus. To further examine a possible
functional role of SARA, we studied the nuclear translocation ofSmad2. We observed a robust nuclear accumulation of Smad2 in
cells treated with non-targeting control siRNA together with
TGF-b (Fig. 2B, panel 2). Importantly, no changes in Smad2 nuclear
translocation upon TGF-b stimulation were detected when SARA
was knocked down using two different siRNAs (Fig. 2B, panel 4,
and data not shown). In order to test whether loss of SARA could
have an inﬂuence on downstream effectors of the TGF-b signaling
pathway despite no reduction in R-Smad phosphorylation, we
monitored the induction of three different TGF-b target genes,
Inhibitor of Differentiation (ID) 1, ID2 and ID3. The expression of
ID1, ID2 and ID3 was increased 2.5- to 5-fold one hour after addi-
tion of TGF-b in control siRNA-treated cells. Of note, the TGF-b-in-
duced upregulation of ID1, ID2 and ID3 was not signiﬁcantly
different in SARA siRNA-treated cells as compared to cells treated
with control siRNA (Fig. 2C). These data show that expression of
the key TGF-b target genes is not inﬂuenced by loss of SARA. Taken
together, our results demonstrate that loss of SARA does not abro-
gate canonical TGF-b signaling or TGF-b-induced target genes, sug-
gesting that SARA is not essential for a functional TGF-b signaling
pathway in HeLa cells.
3.4. SARA does not associate with R-Smads or TGF-b receptors
SARA has been reported as a component of the TGF-b signaling
pathway that facilitates interactions between the R-Smads and the
receptor [10]. We therefore tested for potential complex formation
between SARA and essential TGF-b signaling components from
unstimulated and TGF-b-stimulated cells. We analyzed
rabbit anti-SARA pull-downs by immunoblotting using anti-
Smad2, -Smad1, -Smad5, -Smad3, -TbRI and -TbRII. HeLa cell lysate
was applied as positive control for detection of the different
proteins, and rabbit IgG was included as a negative control. We de-
tected no co-precipitation of neither of the TGF-b signaling-path-
way components analyzed in unstimulated and TGF-b-stimulated
HeLa cells (Fig. 3). Our results show no indications of interaction
between SARA and key components of the TGF-b signaling
pathway.
4. Discussion
The expression and function of the adaptor protein SARA have
been elucidated in studies using many cell types of different origin,
of which the majority were overexpression studies. Some of these
studies demonstrated that SARA is an essential anchor protein for
Smad molecules in the TGF-b signaling pathway, bridging between
the R-Smads and the receptor to facilitate R-Smad phosphorylation
[10,11,17]. However, other studies indicated that TGF-b signaling is
not dependent on SARA to function properly [12,13]. Our data
show no indications that SARA has a role in the TGF-b signaling
pathway in B-cell lymphoma cell lines or HeLa cells, supporting
the latter view. Nearly complete knockdown of SARA with two dif-
ferent siRNAs did not inﬂuence the level of TGF-b-induced R-Smad
phosphorylation and nuclear translocation, or induction of major
TGF-b target genes.
The discrepancy between the observed results, whether SARA
can inﬂuence TGF-b signaling or not, might be due to application
of different cell types from different species in these prior studies.
One of these studies used HeLa cells, and also concluded that SARA
was not essential for TGF-b signaling [13]. Using a Smad2 construct
without the SARA binding domain, this Smad2 variant still inter-
acted with the TbRI and was phosphorylated upon TGF-b stimula-
tion [13]. Another possible explanation for the diversity in the
observed results could be caused by the use of different methods
formanipulating the levels of SARA. In the previous studies, overex-
pression was used to interfere with SARA levels, whereas we used
Fig. 2. SARA knockdown does not abrogate TGF-b canonical signaling. (A) HeLa cells were transfected with non-coding control siRNA, SARA and/or Endoﬁn siRNA, stimulated
with or without TGF-b for 1 h, lysed, and subjected to Western immunoblotting analysis with the indicated primary antibodies. Shown is one representative experiment out
of three or four. Actin was used as loading control. (B) HeLa cells were transfected with non-coding control siRNA or SARA siRNA, stimulated with or without TGF-b for 1 h,
stained with Smad2 antibody and Hoechst to visualize the nuclei and analyzed by confocal microscopy. Shown is one representative experiment out of three. (C) HeLa cells
were transfected with non-coding control siRNA or SARA siRNA and stimulated with or without TGF-b for 1 or 6 h before total RNA was isolated, cDNA was synthesized and
real-time RT-PCR was conducted with the indicated probes. Shown is relative mRNA expression of ID1, ID2 and ID3 (means ± S.E.M., n = 3).
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FYVE-ﬁnger domain-containing proteins can lead to changes in
endosomal structures [18], possibly due to sequestration of the
FYVE ligand PtdIns(3)P as shown for SARA [19,20] and Endoﬁn
[21]. These changes could inﬂuence the TGF-b signaling, as it is sug-
gested that the signaling can occur via internalization of TGF-b
receptors to early endosomes [22,23]. Itoh and co-workers demon-
strated previously that ectopic expression of a FYVE-domain pro-
tein caused redistribution of endogenous SARA, and disruption of
TGF-b signaling [20]. In addition, Hayes and colleagues demon-
strated that overexpression of the FYVE domain could impair
Smad2 nuclear translocation [24]. Overexpressing SARA, both
wild-type and a truncated version, would then possibly lead to im-
paired TGF-b signaling not due to the truncated version of SARA, but
because of overexpression of a FYVE-domain protein per se. The
majority of the cell lines used in these studies are of epithelial ori-
gin, and have endogenous expression of SARA. Previously, it has
been demonstrated that overexpression of Endoﬁn led to aggrega-
tion of endosomes and less EGF degradation [21]. In this work a
more general role for both SARA and Endoﬁn in endosomal sorting
was proposed. Furthermore, various concentrations and isoforms of
TGF-b have been used throughout the different studies. This might
also explain the diversity in the results. We have used moderate
concentrations of TGF-b1 (1 ng/ml) in our experiments involving
HeLa cells. Furthermore, the duration of TGF-b stimulation could
also be essential. We measured Smad2 and Smad1/5 phosphoryla-
tion after one hour of TGF-b stimulation. Zhao and co-workers
showed that only early time points (15 min) of TGF-b-inducedSmad2/3 phosphorylation are impaired when a truncated SARA
protein is overexpressed in NMuMG murine cells, but that TGF-b
signaling appears normal between 30 min and 24 h after TGF-b
stimulation [25]. We measured TGF-b-induced Smad2 activation
after 15 min in control and SARA knockdown cells. However, no dif-
ference in Smad2 phosphorylation was detected (data not shown).
Zhao and Hoffmann only applied the Smad Binding Domain of SARA
in their construct, and tagged it with a Nuclear Localization Se-
quence, which localizes the overexpressed truncated SARA to the
nucleus. In this study, Smad2/3 were localized predominantly to
the nucleus in unstimulated cells, which is different from the nor-
mal physiological distribution of Smad2/3 [26]. In fact, the authors
stated that they cannot exclude that the localization of truncated
SARA inﬂuences the early time points of TGF-b signaling [25].
Endoﬁn is a FYVE-domain protein, whose amino-acid sequence
is 49% homologous to SARA. Endoﬁn was originally found not to be
essential for the TGF-b signaling pathway [21], and later a role in
BMP signaling was proposed [16]. In contrast, another study
showed interaction of Endoﬁn with Smad4 and that Endoﬁn was
essential for normal TGF-b induction of CAGA-Luc in HepG2 and
Hep3B cells [27]. Our data indicate that Endoﬁn is not essential
for TGF-b-induced phosphorylation of Smad2 or Smad1/5, and that
Endoﬁn is not able to substitute for SARA upon loss of SARA. The
discrepancies between our results and the previous study could
again be due to overexpression of FYVE-domain containing pro-
teins in the latter study.
Several studies have shown co-localization between SARA and
EEA1, an early endosomal marker [19,20,24]. Moreover, in many
Fig. 3. SARA does not associate with R-Smads or TGF-b receptors. HeLa cells were
stimulated with or without TGF-b for 5 or 15 min, lysed, and subjected to co-
immunoprecipitation against SARA and subsequently immunoblotted against the
indicated primary antibodies. Shown is one representative experiment out of three.
The heavy chain of Ig was pulled down in the assay, and could be visualized at
50 kDa.
M. Bakkebø et al. / FEBS Letters 586 (2012) 3367–3372 3371studies effects on endosome morphology upon SARA overexpres-
sion have been demonstrated. This could indicate a more general
role for SARA in membrane trafﬁcking. Hu and co-workers showed
evidence that SARA has a functional role downstream of Rab5 in
regulating endosomal trafﬁcking [28]. In this study, overexpression
of SARA resulted in a reduced recycling rate of Transferrin receptor
back to the plasma membrane.
In conclusion, SARA does not seem to have an essential role in
functional TGF-b signaling in B-cell lymphoma or HeLa cells. Addi-
tional research is needed to elucidate whether SARA has a more
general role in membrane trafﬁcking affecting other cytokine
receptors.
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